Sun Pharma sells two U.S. manufacturing units to Frontida BioPharmStaff writer ▼ | June 6, 2016
As a part of its manufacturing consolidation in the U.S., Sun Pharma has entered into an agreement with Frontida BioPharm for sale of its two oral solid dosage manufacturing facilities located at Philadelphia, Pa., and Aurora, Ill., along with 15 related pharmaceutical products.
Selling Manufacturing consolidation
In connection with the transaction, Frontida has agreed to continue manufacturing certain products for Sun Pharma at these facilities on a contract basis for a predetermined period.
Frontida also agreed to offer employment to all production, quality and administrative personnel at the sites. ■